Recent studies indicate the inversely proportional relationship of adiponectin concentration in the blood and metabolic syndrome as well as its anti-inflammatory and anti-atherogenic potential in the treatment of metabolic syndrome and type 2 diabetes (27, 28). Here, ADIPOQ is linked to metabolic syndrome.